We seek 1 – 2 fellows interested in working in clinical and translational research to join our Gastrointestinal Unit located at the Vall d’Hebron University Hospital (HUVH – Vall d´Hebron Barcelona Hospital Campus). The successful candidate (s) will be in charge of patients and clinical trials in gastrointestinal tumors. Mentored by a Senior Consultant of our Unit, the appointed fellow(s) will be involved in clinical studies, molecular prescreening, and our team’s translational projects. Development of investigator-initiated trials and projects will be highly encouraged, as will collaborative research with other VHIO groups.

The duration of the Fellowship will be 1 or 2 years based on prior experience, with the possibility of extension of contract upon review of professional merits and performance.

The selection of the successful candidate(s) is envisaged between October-December 2018. The appointed fellow (s) will be expected to join our Unit by the end of January 2019 at the very latest.

Requirements:

The successful candidate(s) will be Board Certified in Medical Oncology. The main focus of our Gastrointestinal Unit at Vall d´Hebron is the development of new drugs in this setting. This area should therefore be of keen interest to the fellow(s). Previous experience in clinical research will be an added value. Since the fellow(s) will be dealing directly with patients, the ability to communicate well in Spanish is mandatory. Written and spoken English are also required for interaction with study sponsors and investigators.

General description: site location

The Vall d´Hebron University Hospital (HUVH), located within the Vall d´Hebron Barcelona Hospital Campus, is one of the largest and most important hospitals in Spain. HUVH’s Medical Oncology Department, directed by Dr. Josep Tabernero, centers on providing patient care of excellence and the bridging of cutting-edge basic and clinical research, with a determined focus on advancing translational oncology.

Our Gastrointestinal Unit performs early (phase I) and late clinical (phase II and III) studies with novel therapies against gastrointestinal tumors. The main focus of our team is to translate novel targeted therapies and strategies to the clinic and test them in the treatment of gastrointestinal tumors. Our Unit continues to grow from strength, gaining increased visibility and recognition across Europe and beyond.

In addition to our renowned expertise in early clinical drug development and clinical trials design, we also pioneer biomarker development (CTC, Pharmacodynamics, etc.), generate and develop patient-derived xenografts, and perform molecular analyses of tumors for treatment selection. Our institution provides all the essential facilities and technologies for translational research, with various groups focused on cancer-stem cells, cell-signaling, resistance to targeted therapies, genomics, and molecular oncology.

Application:

Potential candidates should send a CV, letter of motivation and the names and contact details of 2-3 references by email to: selecciorrhh@vhio.net.

About VHIO:

Under the leadership of Josep Tabernero, the Vall d’Hebron Institute of Oncology (VHIO), created by José Baselga in 2006, has established itself as a comprehensive cancer center of proven excellence internationally. It is thanks to Josep Tabernero’s directorship and VHIO’s optimal organizational structure based on a purely multidisciplinary and translational model that VHIO talents continue to anticipate and tackle the many unresolved questions in combatting this multifaceted and heterogeneous disease.

Located within the Vall d’Hebron Barcelona Hospital Campus, our researchers closely collaborate and interact with Vall d’Hebron physician-scientists. Translational science and clinical research are therefore tightly connected which promotes superb interaction and teamwork which, in turn, accelerates the bench-bedside-bed cycle of knowledge. This privileged environment affords VHIO direct access to patients as well as the entire spectrum of oncology professionals who care for them, and a second-to-none appreciation of how cancer science can translate into more powerful, targeted treatments and better practice for the care of patients.

VHIO’s pioneering model and programs, coupled with its belief in combining strengths through cross-border collaborations, continue to spur advances in reversing cancer resistance, halting metastatic spread, and more effectively treating even the most undruggable tumor types.